Individual response patterns to sequential trials of different antihypertensive drugs may provide a framework to classify hypertensive patients into biologically relevant groups and simplify treatment.
Heterogeneity of response to antihypertensive therapy is a well-recognized clinical phenomenon. An agent that is antihypertensive in one patient may increase blood pressure in another or have no effect in a third. We believe that this variety of individual response to drug treatment can provide a new framework for the study of hypertensive subjects. Different patterns of response elicited by sequential trials of individual drugs with different mechanisms of action (diuretics, calcium channel blockers, alpha-blockers, beta-blockers, and converting enzyme inhibitors) should provide another means to classify hypertensive patients into biologically relevant groups. The documentation and analysis of this therapeutic heterogeneity in relation to renin profiling and to other physiological and demographic parameters may add a new dimension to the investigation of the pathophysiology of hypertension; it may serve as a basis for more appropriate stratification of participants in clinical trials and may ultimately contribute to a more rational approach to patient management.
Laragh et al. (Thu,) conducted a review in Hypertension. Antihypertensive therapy was evaluated. Individual response patterns to sequential trials of different antihypertensive drugs may provide a framework to classify hypertensive patients into biologically relevant groups and simplify treatment.